H.pylori gastric adenocarcinoma pathophysiology

Jump to: navigation, search

For more information on gastric adenocarcinoma click here.

Helicobacter pylori infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Gastritis
Peptic ulcer disease
Gastric adenocarcinoma
MALT lymphoma

Causes

Differentiating Helicobacter pylori infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Guideline Recommendation

ACG guidelines
ESPGHAN and NASPGHAN guidelines

History and Symptoms

Physical Examination

Diagnostic tests

Endoscopic tests
Nonendoscopic tests

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

H.pylori gastric adenocarcinoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of H.pylori gastric adenocarcinoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on H.pylori gastric adenocarcinoma pathophysiology

CDC on H.pylori gastric adenocarcinoma pathophysiology

H.pylori gastric adenocarcinoma pathophysiology in the news

Blogs on H.pylori gastric adenocarcinoma pathophysiology

Directions to Hospitals Treating Helicobacter pylori infection

Risk calculators and risk factors for H.pylori gastric adenocarcinoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yamuna Kondapally, M.B.B.S[2]

Overview

Gastric cancer is the second leading cause of cancer-related deaths worldwide and H. pylori is the strongest known risk factor for gastric cancer. H. pylori is considered as type I carcinogen. Among infected individuals, 1 to 3% develop gastric adenocarcinoma.

Pathophysiology

Pathogenesis


References

  1. 1.0 1.1 1.2 Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M; et al. (2001). "Helicobacter pylori infection and the development of gastric cancer". N Engl J Med. 345 (11): 784–9. doi:10.1056/NEJMoa001999. PMID 11556297.
  2. Correa P (1992). "Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention". Cancer Res. 52 (24): 6735–40. PMID 1458460.
  3. Blaser MJ (1995). "The role of Helicobacter pylori in gastritis and its progression to peptic ulcer disease". Aliment Pharmacol Ther. 9 Suppl 1: 27–30. PMID 7495938.
  4. Bechi P, Balzi M, Becciolini A, Maugeri A, Raggi CC, Amorosi A; et al. (1996). "Helicobacter pylori and cell proliferation of the gastric mucosa: possible implications for gastric carcinogenesis". Am J Gastroenterol. 91 (2): 271–6. PMID 8607492.
  5. Jarosz M, Dzieniszewski J, Dabrowska-Ufniarz E, Wartanowicz M, Ziemlanski S, Reed PI (1998). "Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice". Eur J Cancer Prev. 7 (6): 449–54. PMID 9926292.
  6. Tsugane S, Sasazuki S (2007). "Diet and the risk of gastric cancer: review of epidemiological evidence". Gastric Cancer. 10 (2): 75–83. doi:10.1007/s10120-007-0420-0. PMID 17577615.
  7. Jakszyn P, Gonzalez CA (2006). "Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence". World J Gastroenterol. 12 (27): 4296–303. PMC 4087738. PMID 16865769.
  8. Stolte M, Bethke B (1990). "Elimination of Helicobacter pylori under treatment with omeprazole". Z Gastroenterol. 28 (6): 271–4. PMID 2238754.

Linked-in.jpg